Results 141 to 150 of about 14,105 (264)

Targeting TNBC: core–shell polycationic polyurea dendrimers with inherent anticancer activity

open access: yesFEBS Open Bio, Volume 16, Issue 5, Page 944-965, May 2026.
Core–shell polycationic PURE dendrimers were tested in TNBC‐derived tumor models. Both formulations selectively targeted TNBC and effectively reduced tumor volume. PUREG4‐OEI48 suppressed tumor growth without detectable toxicity, whereas PUREG4‐OCEI24, despite showing efficacy, induced hepatic toxicity.
Adriana Cruz   +9 more
wiley   +1 more source

Metabolomic associations of impaired awareness of hypoglycaemia in type 1 diabetes

open access: yesScientific Reports
This study investigates impaired awareness of hypoglycaemia (IAH), a complication of insulin therapy affecting 20–40% of individuals with type 1 diabetes.
R. D. M. Varkevisser   +7 more
doaj   +1 more source

The role of lipid metabolism in neuronal senescence

open access: yesFEBS Open Bio, Volume 16, Issue 5, Page 857-869, May 2026.
Disrupted lipid metabolism, through alterations in lipid species or lipid droplet accumulation, can drive neuronal senescence. However, lipid dyshomeostasis can also occur alongside neuronal senescence, further amplifying tissue damage. Delineating how lipid‐induced senescence emerges in neurons and glial cells, and how it contributes to ageing and ...
Dikaia Tsagkari   +2 more
wiley   +1 more source

Immune Checkpoint Inhibitors and Immunomodulators for Cancer Immunotherapy: Insights Into Resistance and Therapeutic Strategies

open access: yesAdvanced Science, Volume 13, Issue 25, 4 May 2026.
The schematic diagram illustrates the roles of novel immune checkpoints, immunomodulatory factors, cell death and multimodal technologies in cancer immunotherapy. Abstract Cancer immunotherapy has redefined cancer treatment. However, the molecular and cellular basis of immune evasion and therapeutic resistance remains incompletely understood.
Fangquan Chen   +7 more
wiley   +1 more source

Beyond Extracellular Vesicle (EV) Hype: Practical Solutions and Remaining Hurdles in EV Research, Manufacturing, and Clinical Translation

open access: yesAdvanced Science, Volume 13, Issue 26, 8 May 2026.
ABSTRACT Extracellular vesicles (EVs) are nanoscale mediators of intercellular communication with diverse molecular cargoes that reflect their cell of origin. Advances in isolation, detection, and single‐particle analytics have revealed increasing molecular and functional heterogeneity, while exposing limitations in how EV identity and activity are ...
David J. Lundy   +8 more
wiley   +1 more source

Lipidome Analysis of Cancer Cells and Their Extracellular Vesicles Reveals Cancer‐Type‐Specific Lipid Signatures and Enables the Design of EV‐Mimetic Liposomes

open access: yesJournal of Extracellular Vesicles, Volume 15, Issue 5, May 2026.
ABSTRACT Lipid metabolism reprogramming is a hallmark of cancer, yet the global lipidome of cancer cells and their extracellular vesicles (EVs) remains poorly understood. Using mass spectrometry, we analyzed the lipid profiles of a panel of human cancer and non‐cancer cell lines along with their secreted EVs.
Noélie Douanne   +14 more
wiley   +1 more source

2025 Consensus Clinical Management Guidelines for Niemann‐Pick Disease Type C

open access: yesJournal of Inherited Metabolic Disease, Volume 49, Issue 3, May 2026.
ABSTRACT In 2018, the International Niemann‐Pick Disease Alliance (INPDA) and the International Niemann‐Pick Disease Registry (INPDR) developed and published comprehensive clinical management guidelines to support inclusive and standardized care pathways in Niemann‐Pick disease type C (NPC)—an ultra‐rare, autosomal recessive, neurovisceral lysosomal ...
Tarekegn Hiwot   +33 more
wiley   +1 more source

Adults With Acid Sphingomyelinase Deficiency Have Sustained Improvements in Clinical Outcomes With up to 5 Years of Olipudase Alfa Enzyme Replacement Therapy: ASCEND Trial Final Results

open access: yesJournal of Inherited Metabolic Disease, Volume 49, Issue 3, May 2026.
ABSTRACT Acid sphingomyelinase deficiency (ASMD) is a rare debilitating lysosomal storage disease resulting in multisystemic disease manifestations, significant disease burden, and early mortality for some individuals. Enzyme replacement therapy (ERT) with olipudase alfa (Xenpozyme) is the first disease‐specific treatment indicated for noncentral ...
Melissa P. Wasserstein   +20 more
wiley   +1 more source

Home - About - Disclaimer - Privacy